Skip to main content
Erschienen in: PharmacoEconomics 3/2002

01.12.2002 | Current Opinion

Reimbursement and Cost Containment

A German Perspective

verfasst von: Professor Dr Friedrich Breyer

Erschienen in: PharmacoEconomics | Sonderheft 3/2002

Einloggen, um Zugang zu erhalten

Abstract

This paper distinguishes short- and long-term financing problems in social health insurance systems in Germany and other European countries. The first part focuses on recent healthcare reforms in Germany that are directed at short-term problems, in particular measures of cost containment in the pharmaceutical sector such as the introduction of a drug formulary and reforms in the system of risk adjustment to enhance competition between sickness funds. The second part discusses the likely effects of the aging of the population on the sustainability of present types of mandatory insurance coverage in Germany and possible reforms that could solve the problems. It is argued that the proposed distinction between basic and supplementary benefits requires a system of explicit rationing (e.g. by age), which determines the package of basic benefits several decades in advance.
Fußnoten
1
This number cannot be interpreted as the share of wages that goes into social insurance. To obtain this share, the employer’s part of 20.6% has to be added to the gross wage. Of this total (120.6% of gross wages), 41 percentage points, or 34%, go into the social insurance system.
 
2
The last revision of this paper was in August 2002, just before the general elections of September 22, 2002.
 
3
See, for example, van de Ven and Ellis.[3] Note that in the presence of community rating, only a perfect system of risk adjustment makes high risks as attractive to the sickness funds as low risks.
 
Literatur
1.
Zurück zum Zitat Hjertqvist J. Meeting the challenges to European healthcare: lessons learned from the ‘stockholm Revolution’. Pharmacoeconomics 2002; 20 Suppl. 3: 47–53PubMedCrossRef Hjertqvist J. Meeting the challenges to European healthcare: lessons learned from the ‘stockholm Revolution’. Pharmacoeconomics 2002; 20 Suppl. 3: 47–53PubMedCrossRef
2.
Zurück zum Zitat Turner G-M. A profile of the health sector in the United States. Pharmacoeconomics 2002; 20 Suppl. 3: 31–45PubMedCrossRef Turner G-M. A profile of the health sector in the United States. Pharmacoeconomics 2002; 20 Suppl. 3: 31–45PubMedCrossRef
3.
Zurück zum Zitat Van de Ven WPMM, Ellis RP. Risk adjustment in competitive health plan markets. In: Culyer AJ, Newhouse JP, editors. Handbook of health economics. Amsterdam: North-Holland, 2000: 755–845 Van de Ven WPMM, Ellis RP. Risk adjustment in competitive health plan markets. In: Culyer AJ, Newhouse JP, editors. Handbook of health economics. Amsterdam: North-Holland, 2000: 755–845
5.
6.
Zurück zum Zitat Breyer F, Kifmann M. Optionen der Weiterentwicklung des Risikostrukturausgleichs in der GKV. DIW Discussion paper no. 236, 2001. Available from URL: http://www.diw.de Breyer F, Kifmann M. Optionen der Weiterentwicklung des Risikostrukturausgleichs in der GKV. DIW Discussion paper no. 236, 2001. Available from URL: http://​www.​diw.​de
7.
Zurück zum Zitat Organisation for Economic Cooperation and Development (OECD) [editorial]. Paris: OECD Economic Outlook; No. 69. Jun 2001 Organisation for Economic Cooperation and Development (OECD) [editorial]. Paris: OECD Economic Outlook; No. 69. Jun 2001
8.
Zurück zum Zitat Eurostat. Demographic Statistics 1999. Luxembourg: Office for Official Publications of the European Communities, 1999 Eurostat. Demographic Statistics 1999. Luxembourg: Office for Official Publications of the European Communities, 1999
9.
Zurück zum Zitat Breyer F, Schultheiss C. ‘Primary’ rationing of health services in ageing societies: a normative analysis. Int J Health Care Finance Econ 2002; In Press Breyer F, Schultheiss C. ‘Primary’ rationing of health services in ageing societies: a normative analysis. Int J Health Care Finance Econ 2002; In Press
Metadaten
Titel
Reimbursement and Cost Containment
A German Perspective
verfasst von
Professor Dr Friedrich Breyer
Publikationsdatum
01.12.2002
Verlag
Springer International Publishing
Erschienen in
PharmacoEconomics / Ausgabe Sonderheft 3/2002
Print ISSN: 1170-7690
Elektronische ISSN: 1179-2027
DOI
https://doi.org/10.2165/00019053-200220003-00009

Weitere Artikel der Sonderheft 3/2002

PharmacoEconomics 3/2002 Zur Ausgabe

Concluding Remarks

Concluding Remarks